Felicia Castriota
Overview
Explore the profile of Felicia Castriota including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
69
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hasegawa M, Sakakibara Y, Takeuchi Y, Sugitani I, Ozono K, Castriota F, et al.
JBMR Plus
. 2024 Aug;
8(9):ziae100.
PMID: 39193114
Hypoparathyroidism is a rare endocrine disorder characterized by low serum calcium and elevated serum phosphorus levels. Patients who do not recover parathyroid function after surgeries or have nonsurgical causes involving...
2.
Jovanovic A, Miller-Hodges E, Castriota F, Takyar S, Howitt H, Ayodele O
Orphanet J Rare Dis
. 2024 Apr;
19(1):181.
PMID: 38689282
Background: Fabry disease (FD) is a rare lysosomal storage disease associated with glycolipid accumulation that impacts multiple physiological systems. We conducted a systematic literature review (SLR) to characterize the humanistic...
3.
Kaul S, Gosmanova E, Castriota F, Hitchens A, Candrilli S, Parikh R, et al.
J Endocr Soc
. 2023 May;
7(5):bvad050.
PMID: 37153700
Hypoparathyroidism (HypoPT) is a rare disease associated with high morbidity. Its economic impact is not well understood. This retrospective, cross-sectional study used data from the United States-based National Inpatient Sample...
4.
Patel H, Wahlstrom S, DerSarkissian M, Kunzweiler C, Castriota F, Chang R, et al.
Expert Rev Pharmacoecon Outcomes Res
. 2023 Apr;
23(6):651-658.
PMID: 37021518
Objectives: Novel therapies improve clinical outcomes in chronic lymphocytic leukemia (CLL), although adverse event (AE) profiles differ. This study evaluated time and personnel costs of AE management among healthcare professionals...
5.
Castriota F, Zushin P, Sanchez S, Phillips R, Hubbard A, Stahl A, et al.
Am J Physiol Endocrinol Metab
. 2020 Feb;
318(5):E667-E677.
PMID: 32045263
The global prevalence of type 2 diabetes (T2D) has doubled since 1980. Human epidemiological studies support arsenic exposure as a risk factor for T2D, although the precise mechanism is unclear....
6.
Castriota F, Rieswijk L, Dahlberg S, La Merrill M, Steinmaus C, Smith M, et al.
Environ Health Perspect
. 2020 Jan;
128(1):16001.
PMID: 31898917
Background: The prevalence of type 2 diabetes (T2D) has more than doubled since 1980. Poor nutrition, sedentary lifestyle, and obesity are among the primary risk factors. While an estimated 70%...
7.
Eick S, Ferreccio C, Acevedo J, Castriota F, Cordero J, Roh T, et al.
Environ Res
. 2019 Mar;
172:578-585.
PMID: 30875511
Objective: Evaluate whether arsenic-related diabetes risks differ between people of low and high socioeconomic status (SES). Methods: We used data collected between October 2007-December 2010 from a population-based cancer case-control...
8.
Castriota F, Acevedo J, Ferreccio C, Smith A, Liaw J, Smith M, et al.
Environ Res
. 2018 Jul;
167:248-254.
PMID: 30059859
Background: The prevalence of type 2 diabetes (T2D) has nearly doubled since 1980. Elevated body mass index (BMI) is the leading risk factor for T2D, mediated by inflammation and oxidative...
9.
Steinmaus C, Castriota F, Ferreccio C, Smith A, Yuan Y, Liaw J, et al.
Environ Res
. 2015 Aug;
142:594-601.
PMID: 26301739
Background: Elevated body mass index (BMI) is a risk factor for cardiovascular disease, diabetes, cancer, and other diseases. Inflammation or oxidative stress induced by high BMI may explain some of...